Karyopharm Therapeutics, Inc. is a biopharmaceutical company focused on the development of novel therapies for cancer and other serious diseases. Its lead product, Xpovio (selinexor), is a first-in-class oral selective inhibitor of nuclear export, which has shown efficacy in treating multiple myeloma and diffuse large B-cell lymphoma. The company operates primarily in the United States and has a growing pipeline of drug candidates targeting various hematological malignancies.
Business Overview
Karyopharm generates revenue primarily through the sale of its lead drug Xpovio, which is priced at approximately $20,000 per year per patient. The company has established partnerships for distribution and is focused on expanding its market presence through clinical trials and regulatory approvals for additional indications.
Regulatory approvals for new indications of Xpovio
Clinical trial results for pipeline candidates
Partnership announcements for distribution or co-development
Market adoption rates of Xpovio in oncology
Risk Factors
Regulatory changes impacting drug approval processes
Technological disruption in cancer treatment methodologies
Emergence of new therapies from competitors targeting the same indications
Pricing pressure from generic alternatives
Liquidity risk due to ongoing R&D expenditures without consistent revenue
Potential for increased debt if additional financing is required for trials
Macro Sensitivity
low - The demand for cancer therapies is relatively inelastic; however, broader economic conditions can impact healthcare spending.
Moderate - Rising interest rates can increase the cost of capital for R&D funding and may impact stock valuations, but the direct impact on demand for cancer therapies is limited.
minimal - The company is not heavily reliant on credit markets for operations, though access to financing is important for ongoing clinical trials.
Profile
growth - Investors looking for high-risk, high-reward opportunities in the biotech space.
high - The stock has shown significant volatility, particularly in response to clinical trial results and regulatory news.
Explore More
Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance